| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alcoholism | 14 | 2021 | 1906 | 1.460 |
Why?
|
| Neurofibromatosis 1 | 14 | 2022 | 569 | 1.400 |
Why?
|
| Neurofibromatosis 2 | 12 | 2018 | 380 | 1.090 |
Why?
|
| Neurofibromatoses | 9 | 2021 | 299 | 0.940 |
Why?
|
| Neurofibroma, Plexiform | 5 | 2022 | 71 | 0.860 |
Why?
|
| Neurilemmoma | 8 | 2021 | 547 | 0.740 |
Why?
|
| Autistic Disorder | 7 | 2010 | 1185 | 0.660 |
Why?
|
| Sex Characteristics | 7 | 2018 | 2585 | 0.630 |
Why?
|
| Language Disorders | 3 | 2010 | 141 | 0.630 |
Why?
|
| Imaging, Three-Dimensional | 12 | 2023 | 4042 | 0.600 |
Why?
|
| Diagnostic Imaging | 7 | 2022 | 3507 | 0.590 |
Why?
|
| Neuroma, Acoustic | 6 | 2014 | 451 | 0.580 |
Why?
|
| Magnetic Resonance Imaging | 59 | 2022 | 35421 | 0.560 |
Why?
|
| Cerebrovascular Circulation | 18 | 2019 | 2731 | 0.550 |
Why?
|
| User-Computer Interface | 2 | 2020 | 1431 | 0.540 |
Why?
|
| Brain | 28 | 2021 | 26385 | 0.490 |
Why?
|
| Frontal Lobe | 12 | 2019 | 1406 | 0.480 |
Why?
|
| Cerebral Angiography | 10 | 2014 | 1285 | 0.470 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 18 | 2000 | 1107 | 0.460 |
Why?
|
| Basal Ganglia | 8 | 1999 | 546 | 0.440 |
Why?
|
| Cerebellum | 4 | 2016 | 1488 | 0.410 |
Why?
|
| Nerve Sheath Neoplasms | 3 | 2022 | 190 | 0.400 |
Why?
|
| Tomography, X-Ray Computed | 26 | 2023 | 20129 | 0.390 |
Why?
|
| Colonography, Computed Tomographic | 2 | 2010 | 169 | 0.390 |
Why?
|
| Clinical Trials as Topic | 9 | 2018 | 7913 | 0.370 |
Why?
|
| Huntington Disease | 5 | 1999 | 1124 | 0.350 |
Why?
|
| Diffusion Tensor Imaging | 3 | 2018 | 2305 | 0.340 |
Why?
|
| Receptors, Muscarinic | 1 | 2009 | 156 | 0.340 |
Why?
|
| Whole Body Imaging | 6 | 2020 | 280 | 0.340 |
Why?
|
| Reward | 3 | 2017 | 941 | 0.340 |
Why?
|
| Ethanol | 2 | 2019 | 1342 | 0.320 |
Why?
|
| Central Nervous System Depressants | 1 | 2009 | 167 | 0.320 |
Why?
|
| Tumor Burden | 8 | 2022 | 1915 | 0.320 |
Why?
|
| Radiographic Image Enhancement | 5 | 2010 | 885 | 0.310 |
Why?
|
| Brain Infarction | 3 | 2018 | 299 | 0.300 |
Why?
|
| Orbital Diseases | 2 | 2000 | 181 | 0.300 |
Why?
|
| Brain Ischemia | 7 | 2019 | 3265 | 0.290 |
Why?
|
| Contrast Media | 10 | 2012 | 5300 | 0.280 |
Why?
|
| Brain Neoplasms | 9 | 2020 | 8863 | 0.280 |
Why?
|
| Orbit | 2 | 2000 | 426 | 0.280 |
Why?
|
| Stroke | 14 | 2019 | 9981 | 0.270 |
Why?
|
| Limbic System | 1 | 2008 | 426 | 0.260 |
Why?
|
| Skin Neoplasms | 7 | 2021 | 5686 | 0.260 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 5 | 2015 | 1184 | 0.260 |
Why?
|
| Computational Biology | 1 | 2017 | 3521 | 0.260 |
Why?
|
| Neurofibroma | 2 | 2022 | 106 | 0.250 |
Why?
|
| Feces | 2 | 2010 | 1401 | 0.250 |
Why?
|
| Image Processing, Computer-Assisted | 13 | 2023 | 8949 | 0.250 |
Why?
|
| Language | 3 | 2017 | 1471 | 0.230 |
Why?
|
| Functional Laterality | 9 | 2017 | 2290 | 0.230 |
Why?
|
| Brain Mapping | 11 | 2019 | 6669 | 0.230 |
Why?
|
| Hippocampus | 3 | 2020 | 3675 | 0.220 |
Why?
|
| Temperance | 2 | 2000 | 89 | 0.220 |
Why?
|
| Neoplasms | 4 | 2020 | 21683 | 0.220 |
Why?
|
| Cerebral Cortex | 13 | 2004 | 5708 | 0.210 |
Why?
|
| Image Enhancement | 2 | 2008 | 2921 | 0.210 |
Why?
|
| Middle Aged | 64 | 2022 | 213383 | 0.210 |
Why?
|
| Cerebellar Cortex | 3 | 2010 | 107 | 0.200 |
Why?
|
| Blood Volume | 4 | 2001 | 565 | 0.200 |
Why?
|
| Arthrogryposis | 1 | 2022 | 72 | 0.200 |
Why?
|
| Humans | 128 | 2023 | 744343 | 0.200 |
Why?
|
| Axons | 1 | 2009 | 1684 | 0.190 |
Why?
|
| Caudate Nucleus | 6 | 2003 | 393 | 0.190 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 4 | 2019 | 2737 | 0.190 |
Why?
|
| Tissue Plasminogen Activator | 3 | 2018 | 1261 | 0.190 |
Why?
|
| Organ Size | 6 | 2020 | 2252 | 0.190 |
Why?
|
| Male | 85 | 2021 | 350118 | 0.190 |
Why?
|
| Adult | 61 | 2022 | 214055 | 0.180 |
Why?
|
| Periosteum | 1 | 2000 | 138 | 0.180 |
Why?
|
| Infarction, Middle Cerebral Artery | 3 | 2009 | 475 | 0.180 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2017 | 3327 | 0.170 |
Why?
|
| Cerebrospinal Fluid | 2 | 1994 | 534 | 0.170 |
Why?
|
| Quinazolines | 3 | 2013 | 1356 | 0.170 |
Why?
|
| AIDS Dementia Complex | 3 | 1995 | 154 | 0.170 |
Why?
|
| Aphasia | 2 | 2010 | 179 | 0.170 |
Why?
|
| Orbital Fractures | 1 | 2000 | 110 | 0.170 |
Why?
|
| Ophthalmologic Surgical Procedures | 2 | 2000 | 349 | 0.170 |
Why?
|
| Thrombolytic Therapy | 6 | 2018 | 2161 | 0.170 |
Why?
|
| Trinucleotide Repeats | 1 | 1999 | 261 | 0.160 |
Why?
|
| Visual Perception | 2 | 2004 | 1420 | 0.160 |
Why?
|
| F2-Isoprostanes | 1 | 2018 | 35 | 0.160 |
Why?
|
| Aged | 47 | 2022 | 163280 | 0.160 |
Why?
|
| Cathartics | 2 | 2010 | 125 | 0.160 |
Why?
|
| Medial Forebrain Bundle | 1 | 2018 | 45 | 0.160 |
Why?
|
| Carboplatin | 1 | 2020 | 801 | 0.150 |
Why?
|
| Female | 74 | 2021 | 380194 | 0.150 |
Why?
|
| Oxidative Stress | 2 | 2019 | 3086 | 0.150 |
Why?
|
| Diencephalon | 1 | 2017 | 56 | 0.150 |
Why?
|
| Algorithms | 7 | 2015 | 13881 | 0.150 |
Why?
|
| Language Tests | 2 | 2010 | 200 | 0.150 |
Why?
|
| Alzheimer Disease | 10 | 2000 | 8037 | 0.150 |
Why?
|
| Endpoint Determination | 2 | 2018 | 601 | 0.150 |
Why?
|
| Osteolysis | 1 | 2018 | 270 | 0.140 |
Why?
|
| Eye Movements | 1 | 2000 | 507 | 0.140 |
Why?
|
| Abscess | 1 | 2000 | 607 | 0.140 |
Why?
|
| Eyelids | 1 | 1999 | 265 | 0.140 |
Why?
|
| Internet | 2 | 2020 | 3064 | 0.140 |
Why?
|
| Putamen | 4 | 1996 | 291 | 0.140 |
Why?
|
| Genetic Association Studies | 4 | 2020 | 2703 | 0.140 |
Why?
|
| Neuropsychology | 1 | 1997 | 110 | 0.140 |
Why?
|
| Heterocyclic Compounds | 2 | 1997 | 249 | 0.140 |
Why?
|
| Germ-Line Mutation | 3 | 2020 | 1788 | 0.140 |
Why?
|
| Oncology Service, Hospital | 1 | 2016 | 57 | 0.130 |
Why?
|
| Visual Cortex | 1 | 2004 | 1149 | 0.130 |
Why?
|
| Obsessive-Compulsive Disorder | 6 | 1996 | 1444 | 0.130 |
Why?
|
| Software | 6 | 2022 | 4443 | 0.130 |
Why?
|
| Cognition | 2 | 2010 | 6770 | 0.120 |
Why?
|
| Information Storage and Retrieval | 1 | 2020 | 824 | 0.120 |
Why?
|
| Reference Values | 8 | 2004 | 4982 | 0.120 |
Why?
|
| Case-Control Studies | 9 | 2021 | 21746 | 0.120 |
Why?
|
| Schwann Cells | 1 | 2014 | 195 | 0.110 |
Why?
|
| Organometallic Compounds | 2 | 1997 | 665 | 0.110 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2014 | 138 | 0.110 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2013 | 122 | 0.110 |
Why?
|
| Attention | 2 | 2019 | 2400 | 0.110 |
Why?
|
| Emotions | 2 | 2019 | 2661 | 0.110 |
Why?
|
| Magnetic Resonance Angiography | 2 | 1997 | 1442 | 0.110 |
Why?
|
| Antineoplastic Agents | 5 | 2018 | 13695 | 0.110 |
Why?
|
| Fibrinolytic Agents | 3 | 2018 | 2158 | 0.100 |
Why?
|
| S100 Proteins | 1 | 2012 | 259 | 0.100 |
Why?
|
| Shoulder Joint | 1 | 2018 | 695 | 0.100 |
Why?
|
| Gadolinium | 2 | 1997 | 952 | 0.100 |
Why?
|
| Analysis of Variance | 4 | 2010 | 6365 | 0.100 |
Why?
|
| Perfusion Imaging | 2 | 2010 | 195 | 0.100 |
Why?
|
| Radiology Department, Hospital | 1 | 2016 | 412 | 0.100 |
Why?
|
| Epothilones | 1 | 2011 | 44 | 0.100 |
Why?
|
| Receptor, erbB-2 | 2 | 2013 | 2416 | 0.100 |
Why?
|
| Neuropsychological Tests | 6 | 2021 | 6993 | 0.100 |
Why?
|
| Pattern Recognition, Automated | 2 | 2015 | 1005 | 0.090 |
Why?
|
| Anisotropy | 2 | 2018 | 1265 | 0.090 |
Why?
|
| Reproducibility of Results | 9 | 2017 | 19905 | 0.090 |
Why?
|
| Benzothiazoles | 1 | 2011 | 248 | 0.090 |
Why?
|
| Prefrontal Cortex | 2 | 2019 | 2147 | 0.090 |
Why?
|
| Neurons | 1 | 2009 | 9338 | 0.090 |
Why?
|
| Kidney Function Tests | 1 | 2012 | 684 | 0.090 |
Why?
|
| Receptor, Muscarinic M1 | 1 | 2009 | 24 | 0.090 |
Why?
|
| Tetrazolium Salts | 1 | 2009 | 96 | 0.090 |
Why?
|
| Nerve Growth Factors | 1 | 2012 | 574 | 0.090 |
Why?
|
| Adolescent | 14 | 2022 | 85781 | 0.090 |
Why?
|
| Intracranial Arterial Diseases | 1 | 2009 | 22 | 0.090 |
Why?
|
| Atrophy | 8 | 2016 | 1583 | 0.090 |
Why?
|
| Collateral Circulation | 1 | 2010 | 287 | 0.090 |
Why?
|
| Muscarinic Agonists | 1 | 2009 | 87 | 0.080 |
Why?
|
| Carbachol | 1 | 2009 | 226 | 0.080 |
Why?
|
| Health Planning Guidelines | 1 | 2009 | 163 | 0.080 |
Why?
|
| Young Adult | 11 | 2022 | 56430 | 0.080 |
Why?
|
| Prospective Studies | 14 | 2022 | 53288 | 0.080 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 2214 | 0.080 |
Why?
|
| Sensitivity and Specificity | 9 | 2012 | 14722 | 0.080 |
Why?
|
| Intelligence | 2 | 2017 | 920 | 0.080 |
Why?
|
| Culture Media, Conditioned | 1 | 2009 | 537 | 0.080 |
Why?
|
| Aging | 2 | 1999 | 8664 | 0.080 |
Why?
|
| Basilar Artery | 1 | 2008 | 200 | 0.080 |
Why?
|
| Carotid Artery, Internal | 1 | 2010 | 445 | 0.080 |
Why?
|
| Ear Neoplasms | 1 | 2008 | 117 | 0.080 |
Why?
|
| Vertebrobasilar Insufficiency | 1 | 2008 | 114 | 0.080 |
Why?
|
| Central Nervous System | 1 | 2015 | 1357 | 0.080 |
Why?
|
| Intracranial Thrombosis | 1 | 2008 | 113 | 0.080 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2016 | 941 | 0.080 |
Why?
|
| Regional Blood Flow | 5 | 2000 | 1525 | 0.080 |
Why?
|
| Temporal Lobe | 4 | 2004 | 1670 | 0.070 |
Why?
|
| Subtraction Technique | 1 | 2010 | 525 | 0.070 |
Why?
|
| Breast Neoplasms | 4 | 2020 | 20822 | 0.070 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2009 | 625 | 0.070 |
Why?
|
| Infusions, Intravenous | 3 | 2013 | 2274 | 0.070 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2009 | 629 | 0.070 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2014 | 2016 | 0.070 |
Why?
|
| C-Reactive Protein | 1 | 2018 | 3778 | 0.070 |
Why?
|
| Radiology | 1 | 2020 | 2100 | 0.070 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2010 | 793 | 0.070 |
Why?
|
| Brain Injuries | 1 | 2018 | 2025 | 0.070 |
Why?
|
| Treatment Outcome | 12 | 2018 | 63114 | 0.070 |
Why?
|
| Communication Disorders | 1 | 2006 | 51 | 0.070 |
Why?
|
| Patient Selection | 1 | 2018 | 4215 | 0.070 |
Why?
|
| Pneumothorax | 1 | 2009 | 379 | 0.060 |
Why?
|
| Vocabulary | 1 | 2006 | 169 | 0.060 |
Why?
|
| Visual Fields | 2 | 2004 | 1047 | 0.060 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 2759 | 0.060 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 3966 | 0.060 |
Why?
|
| Sex Factors | 6 | 2021 | 10397 | 0.060 |
Why?
|
| Memory | 2 | 2020 | 2174 | 0.060 |
Why?
|
| Aged, 80 and over | 15 | 2018 | 57776 | 0.060 |
Why?
|
| Verbal Behavior | 2 | 2004 | 339 | 0.060 |
Why?
|
| Protein Kinase C | 1 | 2009 | 1227 | 0.060 |
Why?
|
| Aphasia, Broca | 1 | 2004 | 50 | 0.060 |
Why?
|
| Kidney | 2 | 2012 | 7186 | 0.060 |
Why?
|
| Mandibular Advancement | 1 | 2004 | 64 | 0.060 |
Why?
|
| Dominance, Cerebral | 3 | 1995 | 635 | 0.060 |
Why?
|
| Child | 10 | 2022 | 77709 | 0.060 |
Why?
|
| Observer Variation | 5 | 2006 | 2593 | 0.060 |
Why?
|
| Cochlear Implantation | 1 | 2008 | 310 | 0.060 |
Why?
|
| Consensus | 2 | 2011 | 2959 | 0.060 |
Why?
|
| Acute Disease | 6 | 2010 | 7149 | 0.060 |
Why?
|
| Cohort Studies | 8 | 2018 | 40561 | 0.060 |
Why?
|
| HIV Seropositivity | 3 | 1994 | 971 | 0.060 |
Why?
|
| Wakefulness | 1 | 2010 | 1245 | 0.050 |
Why?
|
| Psychomotor Performance | 2 | 2010 | 1901 | 0.050 |
Why?
|
| Quality of Life | 4 | 2022 | 12804 | 0.050 |
Why?
|
| Occipital Lobe | 1 | 2004 | 379 | 0.050 |
Why?
|
| Archives | 1 | 2022 | 16 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2018 | 4445 | 0.050 |
Why?
|
| Semantics | 1 | 2006 | 584 | 0.050 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 2038 | 0.050 |
Why?
|
| Predictive Value of Tests | 6 | 2018 | 15076 | 0.050 |
Why?
|
| Thiazoles | 1 | 2009 | 1483 | 0.050 |
Why?
|
| Osteogenesis, Distraction | 1 | 2004 | 219 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 11524 | 0.050 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2008 | 770 | 0.050 |
Why?
|
| Gyrus Cinguli | 1 | 2008 | 1091 | 0.050 |
Why?
|
| Astrocytes | 1 | 2009 | 1270 | 0.050 |
Why?
|
| Blotting, Western | 1 | 2009 | 5179 | 0.050 |
Why?
|
| Brain Diseases | 3 | 1997 | 1563 | 0.050 |
Why?
|
| Educational Status | 2 | 2008 | 2540 | 0.050 |
Why?
|
| Tomography, Emission-Computed | 3 | 1996 | 1144 | 0.050 |
Why?
|
| Numerical Analysis, Computer-Assisted | 1 | 2001 | 125 | 0.050 |
Why?
|
| Time Factors | 6 | 2014 | 40075 | 0.050 |
Why?
|
| Globus Pallidus | 3 | 2003 | 253 | 0.050 |
Why?
|
| Craniofacial Abnormalities | 1 | 2003 | 315 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 17446 | 0.050 |
Why?
|
| Living Donors | 1 | 2005 | 620 | 0.050 |
Why?
|
| Angiography | 1 | 2006 | 1639 | 0.050 |
Why?
|
| Radius Fractures | 1 | 2006 | 501 | 0.050 |
Why?
|
| Glioma | 1 | 2015 | 3401 | 0.050 |
Why?
|
| Recovery of Function | 1 | 2010 | 2925 | 0.050 |
Why?
|
| Colon | 1 | 2008 | 1772 | 0.050 |
Why?
|
| Neural Pathways | 2 | 2017 | 2972 | 0.040 |
Why?
|
| Technetium Tc 99m Exametazime | 3 | 1996 | 68 | 0.040 |
Why?
|
| Audiometry, Pure-Tone | 2 | 2012 | 204 | 0.040 |
Why?
|
| Internship and Residency | 1 | 2020 | 5788 | 0.040 |
Why?
|
| Mutation | 3 | 2016 | 29786 | 0.040 |
Why?
|
| Mandible | 1 | 2004 | 740 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 2012 | 2538 | 0.040 |
Why?
|
| Organotechnetium Compounds | 3 | 1996 | 137 | 0.040 |
Why?
|
| Speech | 1 | 2004 | 540 | 0.040 |
Why?
|
| Reaction Time | 1 | 2006 | 2097 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2015 | 4253 | 0.040 |
Why?
|
| Diplopia | 1 | 2000 | 200 | 0.040 |
Why?
|
| Schizophrenia | 5 | 1997 | 6882 | 0.040 |
Why?
|
| Vision, Binocular | 1 | 2000 | 213 | 0.040 |
Why?
|
| Alprazolam | 1 | 1998 | 98 | 0.040 |
Why?
|
| Preoperative Care | 3 | 2005 | 2250 | 0.040 |
Why?
|
| Nuclear Family | 1 | 1999 | 318 | 0.040 |
Why?
|
| Face | 1 | 2004 | 994 | 0.040 |
Why?
|
| Parietal Lobe | 3 | 2019 | 838 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 6234 | 0.040 |
Why?
|
| Retrospective Studies | 9 | 2012 | 77449 | 0.040 |
Why?
|
| Oximes | 3 | 1996 | 311 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2014 | 19229 | 0.040 |
Why?
|
| Cognition Disorders | 3 | 1998 | 4043 | 0.040 |
Why?
|
| Osteogenesis | 1 | 2004 | 1299 | 0.040 |
Why?
|
| Photic Stimulation | 1 | 2004 | 2025 | 0.040 |
Why?
|
| Facial Expression | 1 | 2021 | 508 | 0.040 |
Why?
|
| Cerebral Ventricles | 2 | 2017 | 544 | 0.040 |
Why?
|
| Fluoxetine | 2 | 1991 | 749 | 0.040 |
Why?
|
| Iopamidol | 2 | 2007 | 191 | 0.040 |
Why?
|
| Schizophrenic Psychology | 2 | 1995 | 1678 | 0.040 |
Why?
|
| Cerebral Infarction | 1 | 2001 | 1011 | 0.030 |
Why?
|
| Mental Disorders | 2 | 1998 | 6600 | 0.030 |
Why?
|
| Radiography | 2 | 2020 | 7023 | 0.030 |
Why?
|
| Pain Measurement | 2 | 2018 | 3420 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2020 | 3508 | 0.030 |
Why?
|
| Behavior | 1 | 2019 | 561 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 11366 | 0.030 |
Why?
|
| Anti-Anxiety Agents | 1 | 1998 | 390 | 0.030 |
Why?
|
| Severity of Illness Index | 6 | 2010 | 15540 | 0.030 |
Why?
|
| Comprehensive Health Care | 1 | 2016 | 127 | 0.030 |
Why?
|
| Phenotype | 3 | 2020 | 16365 | 0.030 |
Why?
|
| Drainage | 1 | 2000 | 1142 | 0.030 |
Why?
|
| Regression Analysis | 3 | 2000 | 6459 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2022 | 5535 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2023 | 11031 | 0.030 |
Why?
|
| Age Factors | 6 | 2012 | 18370 | 0.030 |
Why?
|
| Xenon Radioisotopes | 1 | 1993 | 34 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2013 | 2886 | 0.030 |
Why?
|
| Echo-Planar Imaging | 1 | 1998 | 659 | 0.030 |
Why?
|
| Prognosis | 5 | 2014 | 29063 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2000 | 1486 | 0.030 |
Why?
|
| Hearing Loss | 2 | 2012 | 765 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2018 | 602 | 0.030 |
Why?
|
| Fourier Analysis | 1 | 1994 | 447 | 0.030 |
Why?
|
| Rats | 1 | 2009 | 24260 | 0.030 |
Why?
|
| Swine | 3 | 2009 | 5917 | 0.030 |
Why?
|
| Disease Progression | 3 | 2017 | 13284 | 0.030 |
Why?
|
| Intracranial Hemorrhages | 1 | 2018 | 855 | 0.030 |
Why?
|
| Models, Organizational | 1 | 2016 | 574 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2023 | 3474 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2013 | 6895 | 0.030 |
Why?
|
| Meningioma | 2 | 2011 | 1209 | 0.030 |
Why?
|
| Breast | 1 | 2020 | 1969 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2016 | 1677 | 0.020 |
Why?
|
| Follow-Up Studies | 3 | 2022 | 39050 | 0.020 |
Why?
|
| Physostigmine | 1 | 1991 | 53 | 0.020 |
Why?
|
| Joint Instability | 1 | 2018 | 792 | 0.020 |
Why?
|
| Ischemia | 1 | 2019 | 1907 | 0.020 |
Why?
|
| Receptors, Dopamine D2 | 1 | 1993 | 475 | 0.020 |
Why?
|
| Orbital Neoplasms | 1 | 1992 | 225 | 0.020 |
Why?
|
| Animals | 7 | 2018 | 168757 | 0.020 |
Why?
|
| Surgical Flaps | 1 | 1999 | 1640 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2000 | 6489 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 6538 | 0.020 |
Why?
|
| Kidney Transplantation | 1 | 2005 | 4251 | 0.020 |
Why?
|
| Auditory Brain Stem Implants | 1 | 2009 | 30 | 0.020 |
Why?
|
| Pilot Projects | 3 | 2017 | 8324 | 0.020 |
Why?
|
| Affect | 2 | 1998 | 1476 | 0.020 |
Why?
|
| Brain Damage, Chronic | 1 | 2010 | 265 | 0.020 |
Why?
|
| Reperfusion | 1 | 2010 | 284 | 0.020 |
Why?
|
| Multivariate Analysis | 3 | 2010 | 12245 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2010 | 571 | 0.020 |
Why?
|
| Standard of Care | 1 | 2011 | 564 | 0.020 |
Why?
|
| Normal Distribution | 1 | 2008 | 280 | 0.020 |
Why?
|
| HIV Infections | 1 | 1994 | 16718 | 0.020 |
Why?
|
| Genetic Markers | 1 | 1994 | 2634 | 0.020 |
Why?
|
| Pregnancy | 1 | 2009 | 29144 | 0.020 |
Why?
|
| X-Rays | 1 | 2008 | 301 | 0.020 |
Why?
|
| Decision Trees | 2 | 2000 | 506 | 0.020 |
Why?
|
| Cocaine | 1 | 1993 | 1007 | 0.020 |
Why?
|
| Disease Management | 1 | 2018 | 2459 | 0.020 |
Why?
|
| Risk | 1 | 1999 | 9687 | 0.020 |
Why?
|
| Logistic Models | 2 | 2013 | 13408 | 0.020 |
Why?
|
| Curriculum | 1 | 2020 | 3605 | 0.020 |
Why?
|
| Auditory Threshold | 1 | 2008 | 364 | 0.020 |
Why?
|
| Hemodynamics | 1 | 1997 | 4199 | 0.020 |
Why?
|
| Multiple Trauma | 1 | 2009 | 367 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2010 | 1590 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2016 | 41006 | 0.020 |
Why?
|
| Technology, Radiologic | 1 | 2006 | 163 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2016 | 2616 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2009 | 780 | 0.020 |
Why?
|
| Vestibular Diseases | 1 | 2008 | 217 | 0.020 |
Why?
|
| Glioblastoma | 1 | 2001 | 3481 | 0.020 |
Why?
|
| Linear Models | 2 | 2007 | 5952 | 0.020 |
Why?
|
| Genotype | 1 | 2020 | 12951 | 0.020 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2006 | 168 | 0.020 |
Why?
|
| Ear, Inner | 1 | 2009 | 420 | 0.020 |
Why?
|
| Casts, Surgical | 1 | 2006 | 178 | 0.020 |
Why?
|
| Renal Veins | 1 | 2005 | 108 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2011 | 1017 | 0.020 |
Why?
|
| Cochlear Implants | 1 | 2009 | 339 | 0.020 |
Why?
|
| HIV-1 | 2 | 1993 | 6939 | 0.020 |
Why?
|
| Research Design | 2 | 2011 | 5987 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2009 | 1375 | 0.010 |
Why?
|
| Fracture Fixation | 1 | 2006 | 354 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2016 | 3444 | 0.010 |
Why?
|
| Diagnosis, Differential | 2 | 1996 | 12959 | 0.010 |
Why?
|
| HIV Seronegativity | 2 | 1995 | 211 | 0.010 |
Why?
|
| Reference Standards | 1 | 2007 | 1025 | 0.010 |
Why?
|
| Lymphoma | 1 | 1992 | 1877 | 0.010 |
Why?
|
| Colonic Polyps | 1 | 2008 | 542 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1999 | 13989 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2000 | 7279 | 0.010 |
Why?
|
| Renal Artery | 1 | 2005 | 398 | 0.010 |
Why?
|
| Boston | 1 | 2016 | 9313 | 0.010 |
Why?
|
| Fixation, Ocular | 1 | 2004 | 251 | 0.010 |
Why?
|
| Age Distribution | 1 | 2008 | 2902 | 0.010 |
Why?
|
| Swine, Miniature | 1 | 2004 | 961 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2000 | 7181 | 0.010 |
Why?
|
| Radiosurgery | 1 | 2011 | 1329 | 0.010 |
Why?
|
| Causality | 1 | 2008 | 1275 | 0.010 |
Why?
|
| Models, Neurological | 1 | 2010 | 1774 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2008 | 1359 | 0.010 |
Why?
|
| Tumor Microenvironment | 1 | 2013 | 3586 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2016 | 7729 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 15519 | 0.010 |
Why?
|
| Registries | 1 | 2016 | 8089 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 4851 | 0.010 |
Why?
|
| Colonoscopy | 1 | 2008 | 1367 | 0.010 |
Why?
|
| Endovascular Procedures | 1 | 2014 | 1979 | 0.010 |
Why?
|
| Indans | 1 | 2000 | 96 | 0.010 |
Why?
|
| Meningeal Neoplasms | 1 | 2009 | 1241 | 0.010 |
Why?
|
| Biomedical Research | 1 | 2016 | 3309 | 0.010 |
Why?
|
| Phantoms, Imaging | 1 | 2008 | 2480 | 0.010 |
Why?
|
| Bipolar Disorder | 2 | 1994 | 5027 | 0.010 |
Why?
|
| Somatosensory Cortex | 1 | 2004 | 528 | 0.010 |
Why?
|
| United States | 3 | 2009 | 69872 | 0.010 |
Why?
|
| Nootropic Agents | 1 | 2000 | 160 | 0.010 |
Why?
|
| ROC Curve | 1 | 2007 | 3527 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 18029 | 0.010 |
Why?
|
| Pain | 1 | 2014 | 4986 | 0.010 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2014 | 3658 | 0.010 |
Why?
|
| Infant | 1 | 2000 | 35136 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2014 | 10481 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2005 | 2715 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2018 | 12208 | 0.010 |
Why?
|
| Apoptosis | 1 | 2014 | 9727 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2010 | 9849 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2001 | 1423 | 0.010 |
Why?
|
| Mortality | 1 | 2008 | 2864 | 0.010 |
Why?
|
| Markov Chains | 1 | 2000 | 969 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2010 | 6196 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 2 | 2000 | 5391 | 0.010 |
Why?
|
| Motor Cortex | 1 | 2004 | 986 | 0.010 |
Why?
|
| Substance-Related Disorders | 1 | 1993 | 4258 | 0.010 |
Why?
|
| Demography | 1 | 2001 | 1656 | 0.010 |
Why?
|
| Models, Economic | 1 | 2000 | 713 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1991 | 6256 | 0.010 |
Why?
|
| Cost Savings | 1 | 2001 | 926 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 8642 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 25043 | 0.010 |
Why?
|
| Comorbidity | 1 | 2010 | 10388 | 0.010 |
Why?
|
| Risk Factors | 2 | 2013 | 72290 | 0.010 |
Why?
|
| Chronic Disease | 2 | 2004 | 9146 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1996 | 798 | 0.010 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2000 | 1683 | 0.010 |
Why?
|
| Prevalence | 1 | 2010 | 15226 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2008 | 5102 | 0.010 |
Why?
|
| Homosexuality | 1 | 1993 | 262 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 1998 | 2029 | 0.010 |
Why?
|
| Oxygen | 1 | 2004 | 4189 | 0.010 |
Why?
|
| Thinking | 1 | 1995 | 319 | 0.010 |
Why?
|
| Mental Status Schedule | 1 | 1993 | 321 | 0.010 |
Why?
|
| Piperidines | 1 | 2000 | 1602 | 0.010 |
Why?
|
| Receptors, Dopamine | 1 | 1993 | 295 | 0.010 |
Why?
|
| Double-Blind Method | 2 | 1998 | 12026 | 0.010 |
Why?
|
| Meta-Analysis as Topic | 1 | 1996 | 1344 | 0.010 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 1996 | 719 | 0.010 |
Why?
|
| Amphetamines | 1 | 1991 | 148 | 0.010 |
Why?
|
| Deoxyglucose | 1 | 1991 | 337 | 0.010 |
Why?
|
| Age of Onset | 1 | 1997 | 3271 | 0.010 |
Why?
|
| Psychological Tests | 1 | 1992 | 651 | 0.010 |
Why?
|
| Anthropometry | 1 | 1994 | 1350 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2001 | 3589 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1993 | 2008 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1992 | 1880 | 0.000 |
Why?
|
| Homosexuality, Male | 1 | 1995 | 1240 | 0.000 |
Why?
|
| Health Care Costs | 1 | 2000 | 3209 | 0.000 |
Why?
|
| Anxiety | 2 | 1991 | 4297 | 0.000 |
Why?
|
| Sequence Analysis, DNA | 1 | 1996 | 4803 | 0.000 |
Why?
|
| Social Class | 1 | 1994 | 1999 | 0.000 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1995 | 6038 | 0.000 |
Why?
|
| Amygdala | 1 | 1992 | 1315 | 0.000 |
Why?
|
| Glucose | 1 | 1996 | 4397 | 0.000 |
Why?
|
| Radiation Dosage | 1 | 1992 | 1928 | 0.000 |
Why?
|
| Drug Administration Schedule | 1 | 1991 | 4933 | 0.000 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1991 | 10943 | 0.000 |
Why?
|